Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMB305 and Atezolizumab in NY-ESO-1 Expressing Sarcoma
NCT02609984Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Primary completion
- Feb 2019
- Modality
- Vaccine mRNA, mRNA Vaccines, Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CMB305 in synovial sarcoma (SS), myxoid liposarcoma (MLPS), myxoid/round cell liposarcoma (MRCLS), sponsored by Merck & Co.. Started Apr 2015; status: terminated.
02
Drugs
CMB305
03
Conditions
synovial sarcoma (SS)myxoid liposarcoma (MLPS)myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NCT02609984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609984.